[Evaluation of cellular and humoral immunity and individual sensitivity of T-lymphocytes to immunocorrectors in patients with diabetic retinopathy].
Zhaboiedov. H D HD; Bychkova. N H NH; Skrypnik. R L RL; Sydorova. M V MV
Key Findings
- Diabetic retinopathy patients exhibited T‑cell immune insufficiency.
- Immune‑correcting agents (splenin, thymalin, erbisol, thymogen) were tested for effectiveness.
- Therapy was individualized by measuring each patient’s T‑cell sensitivity to the drugs.
Practical Outcomes
- For most biohackers, the findings are of limited direct use because they involve a specific disease group. The data suggest thymogen might help immune function in compromised individuals, but there’s no clear protocol for healthy people seeking longevity benefits. More research is needed before recommending it as a routine supplement.
Summary
The study looked at people with diabetic eye disease and found their T‑cell immune system was weak. They tried several immune‑boosting drugs, including the peptide thymogen, and adjusted the choice based on how each person’s T‑cells responded.
Abstract
Patients with diabetic retinopathy were studied for parameters characterizing cell-bound and humoral immunity. Revealed in the course of our study was T-cell immune insufficiency affecting processes of proliferation of T-lymphocytes and warranting adoption of immune correction therapy. Administration of immune correctors was individualized judging from sensitivity of T-lymphocytes to the drugs being employed (splenin, thymalin, erbisol, and thymogen).
Study Information
pubmed
2001